Ecuador Medical Device Tecnovigilancia: Article 70 Post-Market Vigilance Duties

1. Key takeaways

Article 70 of the substitute technical health regulation places the national technical vigilance system (Sistema Nacional de Tecnovigilancia) on a statutory footing. The article names five groups that must cooperate with the system — the holder of the health registration certificate, the legal representative, the technical director of the establishment that manufactures, imports and commercialises the device, health professionals, and general users (usuarios en general) — and it defines the content of that cooperation as the identification, prevention and reporting to ARCSA of reportable adverse events associated with the use of medical devices.

Three features of the drafting carry the practical weight: the length of the list of duty bearers, the fact that reporting is only the last of three verbs, and the qualifier reportable, which presupposes a criterion that the article itself does not supply.

Article 70 also does not operate alone. Article 19 holds the certificate holder responsible for the truthfulness of the information it supplies and for compliance across five stages — manufacturing, storage, distribution, transport and sale — while Article 72 routes any breach of the regulation to the Organic Health Law and other laws in force, without prejudice to civil, administrative and criminal liability. Vigilance sits inside a wider liability structure rather than beside it.

2. Legal basis

Article 70 states the obligation; the definitions on which it relies, including those relating to vigilance, sit in Article 3, and Article 71 separately requires establishments to keep the holder’s distribution authorisation on site for inspection. The Organic Health Law supplies the surveillance and control power in Article 132, to which the sanction route in Article 72 returns.

3. Expert insights

Insight one: the list of duty bearers is longer than most companies expect. Article 70 addresses five classes of subject: the certificate holder, the legal representative, the technical director of the relevant establishment, health professionals, and general users. Writing general users into the list makes the vigilance system open-ended. A report can enter from a hospital, a clinician or a patient, so a manufacturer that controls its distributor does not thereby control the flow of information about its own device.

Insight two: the three duties are identification, prevention and reporting, in that order. The Spanish wording is identificación, prevención y reporte. Identification implies a monitoring process that runs before anything is reported; prevention implies corrective action, and where necessary field action, on the basis of what has been identified; reporting is the visible artefact of the first two. A holder that acts only when a complaint arrives has inverted the sequence and will struggle to evidence prevention at all.

Insight three: the object of the report is a reportable adverse event associated with device use. The source phrase is eventos adversos reportables, asociados al uso de los dispositivos médicos. The qualifier reportable presupposes a threshold or a list, and the article does not reproduce it; the criteria sit in the rules of the national technical vigilance system. A manufacturer should therefore map its own severity classification against the local criterion instead of transposing a threshold used for FDA or EU reporting.

Insight four: Article 19 stacks an independent duty on the same holder. Article 19 covers the truthfulness of the information supplied and compliance across manufacturing, storage, distribution, transport and sale; Article 70 adds vigilance. The two run in parallel, so a clean manufacturing and distribution record does not discharge the vigilance duty, and a vigilance failure can equally be read as an Article 19 failure concerning the information the holder has supplied.

Insight five: Article 72 supplies the sanction channel, and that channel is triple. Violations are sanctioned under the Organic Health Law and other laws in force, and the regulation states expressly that this is without prejudice to civil, administrative and criminal liability. Concealment and late reporting can therefore trigger all three at once. The absence of a penalty figure inside the regulation is not a sign of a light regime; it means the amount is looked up in the parent law.

4. Practical recommendations

1. Fix the executing party and the response time for vigilance in the agreement with the holder: who reports, within how many hours, and what receipt is returned.
2. Build a Chinese–Spanish adverse event reporting template so that translation does not consume the reporting window.
3. Require the holder to give the manufacturer access to the vigilance system and to forward submission receipts, creating a traceable record chain.
4. Assess severe-event response capability when selecting a holder, not only channel reach and commercial terms.
5. Build an internal collection mechanism covering distributors, healthcare institutions and end users, so that identification does not depend on the holder alone.

5. Verification checklist

• □ The agreement allocates the executing party and the response time for vigilance
• □ A bilingual adverse event reporting template has been established
• □ A mechanism for obtaining submission receipts from the vigilance system exists
• □ The holder has been assessed on severe-event response capability
• □ An internal vigilance information collection mechanism has been established
• □ The criteria for a reportable adverse event have been identified

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation